Clinical trials: Histological Response
Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients…
- Conditions
- Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT06784167
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- OHSU Knight Cancer Institute
Retroperitoneal Sarcoma
The PET- Retroperitoneal Sarcoma Study
Retroperitoneal sarcoma(RPS) is a rare cancer that is difficult to cure as it typically presents as a very large abdominal mass, and complete removal with clear margins is challenging .
- Trial name
- PET-RPS (NCT04224948)
- Testing
- PET MRI scan
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- University Health Network, Toronto
Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
This phase II trial studies how well carfilzomib with or without rituximab work in treating patients with Waldenstrom macroglobulinemia or marginal zone lymphoma that is previously untreated, has come back, or does not respond to…
- Conditions
- Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Marginal Zone Lymphoma
- Trial name
- NCT03269552
- Testing
- Carfilzomib, Laboratory Biomarker Analysis, Rituximab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Washington
Newly Diagnosed High Risk Neuroblastoma
Response-based Treatment of High-risk Neuroblastoma
The purpose of this study is to improve outcome of high risk neuroblastoma by tailoring the treatment intensity of tandem high dose chemotherapy according to the treatment response to induction chemotherapy.
- Trial name
- NCT02771743
- Testing
- Cisplatin, Doxorubicin, Etoposide
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Samsung Medical Center
Melanoma (Skin)
Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate
RATIONALE: Studying samples of tissue in the laboratory from patients receiving carboplatin and paclitaxel with or without sorafenib tosylate may help doctors learn more about the effects of this treatment on cells.
- Trial name
- NCT01209299
- Testing
- DNA methylation analysis, gene expression analysis, laboratory biomarker analysis
- Volunteers
- 80 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Leukemia, Myeloid, Chronic-Phase
Pioglityazone and Imatinib for CML Patients
This project is a Phase II clinical trial that aims at evaluating efficacy and tolerance of the combination of pioglitazone (Actos®) and imatinib mesylate (STI571, CGP57148, Gleevec®) in patients with Chronic Myelogenous Leukemia…
- Trial name
- ACTIM (NCT02888964)
- Testing
- Add-on therapy
- Where
- 9 sites in France
- Volunteers
- 27 people
- Sponsor
- Versailles Hospital
Carcinoma, Non-Small-Cell Lung, Thymus Neoplasms
18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma
Background: Imaging studies like positron emission tomography (PET) and computed tomography (CT) scans are used to detect tumor responses to cancer treatment.
- Trial name
- NCT01610544
- Testing
- 3'-deoxy-3'-18F fluorothymidine (FLT), PET/CT scan
- Sponsor
- National Cancer Institute (NCI)
Colorectal Neoplasm, Anemia
Intravenous Iron: Measuring Response in Anemic Surgical Patients
20 Patients will be recruited with confirmed colorectal adenocarcinoma and anemia who are planned to undergo surgery. All patients will be treated with a single dose of 1g intravenous ferric carboxymaltose (FERINJECT).
- Trial name
- NCT02057471
- Testing
- Intravenous ferric carboxymaltose
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Glioblastoma
Predicting Response Patterns to Treatment in Glioblastoma (GBM) Patients
PROPHETIC GBM - Predicting response patterns to treatment in Glioblastoma (GBM) oncology patients based on host response evaluation during anti-cancer treatments
- Trial name
- PROPHETIC (NCT04219475)
- Where
- 4 sites in Israel
- Volunteers
- 1,000 people
- Sponsor
- OncoHost Ltd.
Epithelial Neoplasms, Malignant, Epithelial Tumors, Malignant
NHS-IL12 for Solid Tumors
Background: The experimental drug NHS-IL12 may help the immune system become more active and kill cancer cells that have not responded to standard treatments.
- Conditions
- Epithelial Neoplasms, Malignant, Epithelial Tumors, Malignant, Malignant Mesenchymal Tumor
- Trial name
- NCT01417546
- Testing
- NHS-IL-12
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
This study will test whether an experimental drug called Revlimid (lenalidomide) can reduce tumor size and prolong survival in patients with metastatic melanoma (melanoma that has spread beyond the original tumor site).
- Trial name
- NCT00109005
- Testing
- Revlimid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Hepatocellular
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
This is a study to investigate the potential clinical benefit of refametinib when given in combination with sorafenib as first line treatment in patients with unresectable or metastatic HCC carrying a RAS mutation.
- Trial name
- NCT01915602
- Testing
- Refametinib (BAY86-9766), Sorafenib (BAY43-9006)
- Where
- 79 sites in United States, Austria and 19 more
- Volunteers
- 14 people
- Sponsor
- Bayer
Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN)
MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Background: Neurofibromatosis type 1 (NF1) is a disorder that can cause plexiform neurofibromas (PNs). These are tumors that grow along nerves. Some PNs cause serious health problems.
- Trial name
- NCT02407405
- Testing
- Selumetinib
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma
This is a phase III randomized clinical trial of definitive radiotherapy plus EGFR blocker nimotuzumab versus radiotherapy plus cisplatin(CCRT) for nasopharyngeal carcinoma (NPC) patients with favorable response to induction…
- Trial name
- NCT04456322
- Testing
- RT plus Nimotuzumab, RT plus Cisplatin
- Where
- China
- Volunteers
- 381 people
- Sponsor
- Sun Yat-sen University
Sarcoma
PET Scan Combined With CT Scan in Evaluating Treatment Response in Patients Undergoing Treatment for Bone Cancer or Soft Tissue Sarcoma
RATIONALE: Diagnostic procedures, such as PET scan and CT scan, may help doctors determine the extent of cancer and predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00335751
- Testing
- positron emission tomography computed tomography (PET/CT)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Malignant Epithelial Mesothelioma, Adenocarcinoma of the Pancreas
Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment
This clinical trial will evaluate the safety and tolerability of CRS 207 an investigational product that is a weakened form (attenuated) of Listeria monocytogenes, a type of bacteria that is commonly found in the environment.
- Conditions
- Malignant Epithelial Mesothelioma, Adenocarcinoma of the Pancreas, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma of the Ovaries
- Trial name
- NCT00585845
- Testing
- CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
- Where
- 4 sites in United States, Israel
- Volunteers
- 17 people
- Sponsor
- Anza Therapeutics, Inc.
Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
In this phase II multicenter trial we plan to use acalabrutinib before and after allogeneic hematopoietic stem cell transplantation (alloSCT) with reduced intensity conditioning (RIC) in patients with refractory/relapsed MCL and…
- Conditions
- Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease, Mantle Cell Lymphoma, Adverse Event
- Trial name
- ACALLO (NCT04716075)
- Testing
- Acalabrutinib 2x100 MG Oral Capsule + alloSCT
- Where
- 6 sites in Poland
- Volunteers
- 29 people
- Sponsor
- Polish Lymphoma Research Group
Head and Neck Cancer, Oropharyngeal Cancer
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
The purpose of this study is to investigate the role of the immune system in the response of squamous cell cancers of the head and neck to treatment that includes radiation therapy.
- Conditions
- Head and Neck Cancer, Oropharyngeal Cancer, Human Papillomavirus, Squamous Cell Cancer
- Trial name
- NCT01358097
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma
- Trial name
- NCT03878524
- Testing
- Abemaciclib, Abiraterone, Afatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Response, Acute Phase, Survivorship
Two Schemes Response in Multiple Myeloma
Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination.
- Trial name
- NCT06284395
- Testing
- Bortezomib
- Where
- Mexico
- Volunteers
- 83 people
- Sponsor
- Hospital General de Mexico
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.